DTC
ACRS icon

Deep Track Capital’s Aclaris Therapeutics ACRS Stock Holding History

Deep Track Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4M Hold
9,345,000
– – 0.72% 40
2026
Q1 		$35M Buy
+9,345,000
New +$31.5M 0.57% 42
2023
Q2 		– Sell
-1,708,971
Closed -$13.8M – 56
2023
Q1 		$13.8M Buy
+1,708,971
New +$21.7M 0.57% 43

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deep Track Capital's ACRS Position: Q2 2026 in Review

Deep Track Capital held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 9,345,000 shares worth $49.4M. The position accounts for 0.72% of the portfolio, ranked #40.

Deep Track Capital first reported a position in ACRS in Q1 2023 and has held it in 3 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Deep Track Capital held 9,345,000 shares of Aclaris Therapeutics worth $49.4M as of Q2 2026.
  • Deep Track Capital left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up 0.72% of Deep Track Capital's portfolio in Q2 2026, its #40 holding.
  • Deep Track Capital first reported a position in Aclaris Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.